Faculty Articles

Immunologic status correlates with severity of physical symptoms and perceived illness burden in chronic fatigue syndrome patients

Publication Title

Journal of Chronic Fatigue Syndrome

ISSN

1057-3321

Publication Date

1-1-2000

Abstract

An open labeled, phase 1, safety and feasibility study using lymph node extraction, ex vivo lymph node cell expansion, followed by autologous cell reinfusion was evaluated as a potential immunomodulatory treatment strategy in patients with chronic fatigue syndrome (CFS). The experimental therapy utilized the cells of the lymph node, activated and grown in culture with defined media, interleukin-2 (IL-2) and anti-CD3 to activate and enhance cellular immunological functions. This procedure was designed to change the cytokine pattern of the lymph node lymphocytes to favor expression of T-helper (Th)l-type over Th2-type cytokines. The mixed population of ex vivo immune-enhanced cells were reinfused into the donor, who was carefully monitored for adverse events and possible clinical benefit. There were no adverse events. There were significant improvements in clinical status in association with a significant decrease in Th2-type cytokine production.

Volume

7

Issue

1

First Page

39

Last Page

52

Disciplines

Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy

This document is currently not available here.

Peer Reviewed

Find in your library

Share

COinS